Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598196 | 0.82 | ALOX5AP (0.34) | ALOX5AP | |
| SCHEMBL643186 | 0.81 | KDM4E (0.40) | KDM4EHSD17B10NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL4180932 | 0.80 | KDM4E (0.42) | KDM4EHSD17B10NOS3NOS2 | |
| SCHEMBL9347230 | 0.75 | — | — | |
| SCHEMBL5207671 | 0.75 | HTR2A (0.36) | — | |
| SCHEMBL6622199 | 0.74 | MAOB (0.34) | KDM4E | |
| SCHEMBL590533 | 0.74 | AKT2 (0.35) | — | |
| SCHEMBL1179209 | 0.72 | CA2 (0.42) | — | |
| SCHEMBL2745021 | 0.71 | LTA4H (0.38) | — | |
| SCHEMBL304399 | 0.71 | TYR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| EP-2094689-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | RB1, INMT, IDH3A | KDM4E 50/4885HSD17B10 1155/4885NOS3 2383/4885 |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | KDM4E 199/4885HSD17B10 769/4885NOS3 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.